EnclomiphenevsSermorelin

Enclomiphene is the trans-stereoisomer of clomiphene citrate, a selective estrogen receptor modulator (SERM). Clomiphene (Clomid) contains a roughly equal mixture of two geometric isomers: enclomiphene (trans) and zuclomiphene (cis). Enclomiphene is the pharmacologically desired isomer for testosterone elevation because it acts as a pure estrogen receptor antagonist in the hypothalamus and pituitary, while zuclomiphene has mixed agonist/antagonist activity that can cause unwanted estrogenic effects and has a much longer half-life (weeks), accumulating with chronic dosing.

Enclomiphene competitively binds to estrogen receptors (ERα) in the hypothalamus and anterior pituitary gland, blocking the binding of circulating estradiol. Normally, estradiol exerts negative feedback on the hypothalamic-pituitary axis: estradiol binding to ERα in the hypothalamus reduces GnRH pulse frequency and amplitude, while estradiol binding in the pituitary reduces gonadotroph sensitivity to GnRH. By blocking these receptors, enclomiphene removes the negative feedback signal — the hypothalamus 'perceives' low estrogen levels regardless of actual estradiol concentrations and responds by increasing GnRH pulse frequency. The pituitary, also freed from estrogen-mediated suppression, responds more robustly to each GnRH pulse, producing increased LH and FSH secretion.

Elevated LH stimulates Leydig cells in the testes to produce more testosterone (via the LHCGR/cAMP/StAR steroidogenic pathway), while elevated FSH stimulates Sertoli cells to support spermatogenesis. This is the critical advantage of enclomiphene over exogenous testosterone replacement: it raises endogenous testosterone production through the natural HPG axis while preserving (and potentially enhancing) fertility. Exogenous testosterone, by contrast, suppresses LH/FSH through negative feedback, causing testicular atrophy and often azoospermia. The 10-hour half-life of enclomiphene allows once-daily dosing, and its pure antagonist profile at ERα avoids the estrogenic side effects (hot flashes, visual disturbances, mood changes) that zuclomiphene contributes in mixed clomiphene formulations.

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH 1-44). These 29 residues contain the full biological activity domain required for GHRH receptor activation — the remaining 15 amino acids of native GHRH are not necessary for receptor binding or signal transduction.

Sermorelin binds to the GHRH receptor on anterior pituitary somatotrophs, activating the Gs/adenylyl cyclase pathway to increase intracellular cAMP. This triggers PKA-mediated phosphorylation of CREB and stimulates both GH gene transcription and the release of pre-formed GH vesicles. Because sermorelin works through the body's own regulatory system, GH release occurs in a physiological pulsatile pattern governed by the interplay between GHRH stimulation and somatostatin inhibition — the hypothalamic-pituitary feedback loop remains intact.

This preservation of feedback regulation is sermorelin's primary safety advantage over exogenous GH administration. The pituitary gland can only release as much GH as it has synthesized, providing a natural ceiling effect that prevents supraphysiological GH levels. Somatostatin feedback still functions normally, ensuring appropriate pulse spacing. Additionally, because the pituitary itself is being stimulated rather than bypassed, sermorelin may help maintain or even restore pituitary somatotroph function over time. It was the first GHRH analogue to receive FDA approval (as Geref), specifically for evaluating pituitary GH reserve and treating pediatric GH deficiency, giving it one of the longest clinical track records among GH-stimulating peptides.